Teligent Inc  

(Public, NASDAQ:TLGT)   Watch this stock  
Find more results for TLGT
3.53
-0.06 (-1.67%)
Apr 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.45 - 3.67
52 week 2.43 - 9.54
Open 3.57
Vol / Avg. 442,061.00/937,520.00
Mkt cap 188.50M
P/E     -
Div/yield     -
EPS -0.14
Shares 53.50M
Beta 0.72
Inst. own 88%
Mar 20, 2018
Teligent Inc at Oppenheimer Healthcare Conference
Mar 15, 2018
Q4 2017 Teligent Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin 8.59% -11.43%
Operating margin -30.70% -17.54%
EBITD margin - -10.47%
Return on average assets 2.89% -4.12%
Return on average equity 11.64% -15.16%
Employees 183 -
CDP Score - -

Address

105 Lincoln Avenue
BUENA, NJ 08310
United States - Map
+1-609-6971441 (Phone)
+1-856-6971442 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.

Officers and directors

James C. Gale Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Jason Grenfell-Gardner President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Damian Finio Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Stephen Richardson Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Thomas J. Sabatino Jr. Director
Age: 59
Bio & Compensation  - Reuters
Carole S. Ben-Maimon M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
John E. Celentano Independent Director
Age: 57
Bio & Compensation  - Reuters
Bhaskar Chaudhuri Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Steven Hubrig Koehler Independent Director
Age: 66
Bio & Compensation  - Reuters